Others reported the gemcitabine + olaparib combination induced RAD51 focus formation in pancreatic cancer cells which was attenuated upon co-treatment with CHK1 inhibitors (MK-8776 or prexasertib) [30, 59]. Here, RAD51 is linked to pancreatic neoplasm.